The Feasibility of Overnight Time Restricted Eating and Impact on Glucose Levels in Shift Workers
TREsh
The Effect of Overnight Time Restricted Eating on Glucose Regulation in Rotating Shift Workers - A Randomised Controlled Feasibility Trial
1 other identifier
interventional
31
1 country
1
Brief Summary
The aim of this clinical trial is to assess whether it is feasible for shift workers to follow a time-restricted eating diet. The trial will investigate the impact of time-restricted eating on blood glucose levels during day and night shifts both with and without the time-restricted eating diet. The trial aims are:
- Is it feasible for shift workers to adhere to a night time time-restricted eating protocol?
- How does time-restricted eating affect blood glucose levels during the day and night shifts and over the whole day?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 4, 2024
CompletedFirst Posted
Study publicly available on registry
November 13, 2024
CompletedStudy Start
First participant enrolled
March 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 10, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2025
CompletedDecember 22, 2025
June 1, 2025
4 months
November 4, 2024
December 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Feasibility of time-restricted eating (TRE) among shift workers (Recruitment and Participation Rate)
Feasibility will be assessed through a composite of the following metrics: Recruitment and participation rate (%) will be assessed as the percentage of participants randomized from the screened population. Each component will be assessed separately but reported as contributing factors to the overall feasibility.
From enrolment to end of treatment at 2 weeks
Feasibility of time-restricted eating (TRE) among shift workers (Adherence Rate)
Feasibility will be assessed through a composite of the following metrics: Adherence rate (%) percentage of participants who comply with the TRE protocol over a 2-week period, determined using self-reports Each component will be assessed separately but reported as contributing factors to the overall feasibility.
Two weeks
Feasibility of time-restricted eating (TRE) among shift workers (Study Completion Rate)
Feasibility will be assessed through a composite of the following metrics: Study completion rate (%) percentage of participants who complete the 2-week study period without dropping out. Each component will be assessed separately but reported as contributing factors to the overall feasibility.
Two weeks
Secondary Outcomes (2)
Blood glucose levels during the 2-week study period
2 weeks
Facilitators and barriers associated with adherence to time restricted eating
2 weeks
Study Arms (2)
Time Restricted Eating
EXPERIMENTALParticipants will follow a time-restricted eating diet during day and night shifts over 2 weeks
Control Arm
NO INTERVENTIONParticipants will follow their usual eating patterns without restrictions during day and night shifts over 2 weeks
Interventions
The intervention arm will consist of a time-restricted eating protocol with fasting between 11:00 PM to 6:00 AM. Ad libitum eating will be allowed outside these times and the protocol will be administered during day and night shifts over a 2 week period.
Eligibility Criteria
You may qualify if:
- Healthcare professionals engaged in rotating shift work, including night shifts;
- Aged 23-60 years;
- At least 12 months experience in shift work;
- Willing to wear continuous glucose monitor sensors;
- Willing to engage in time restricted eating.
You may not qualify if:
- Diagnosis of diabetes (Type 1 or 2), any bariatric surgery, coeliac disease, inflammatory bowel disease, endocrine disorders affecting glucose metabolism, current or history of eating disorder, any liver, kidney, or coronary heart disease, obese (BMI\>35) or underweight (BMI\< 18) or any severe or unstable chronic medical conditions or cancers;
- Currently taking medications known to interact with glucose metabolism, i.e. thyroxin, insulin sensitizers, glucocorticoids, or anti-depressants, weight loss medication;
- Undertaking current structured or restrictive dietary plan;
- Shift workers who routinely do not eat between 23:00 and 06:00 hours during night shift;
- Current or planned pregnancy or currently breast feeding;
- Consume three or more standard alcohol containing beverages on a single occasion almost every day;
- People who identify as having significant caffeine dependency and are unwilling to limit intake of calorie free energy drinks;
- People with planned travel over time zones during the study period
- Any contraindication to use of Abott FreeStyle Libre Pro glucose sensor (eg prescription of vitamin C, Salicylic acid or paracetamol - to be reviewed by study clinician).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Sutherland Hospital
Caringbah, New South Wales, 2229, Australia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christopher J Gordon, PhD
Woolcock Institute of Medical Research and Macquarie University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 4, 2024
First Posted
November 13, 2024
Study Start
March 24, 2025
Primary Completion
July 10, 2025
Study Completion
September 1, 2025
Last Updated
December 22, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share
All data will be dei-dentified using a unique study ID.